Abstract:Background: Xenotransplantation using porcine cells, tissues or organs is a promising method to alleviate the shortage of donated cadaveric human organs. Cross-species transmission of an infectious agent from the pig graft to the recipient, hepatic impact caused by an instant blood-mediated reaction, chronic over-immunosuppression and long-term potential infectious risk are the main concerns regarding xenotransplantation. Therefore, we designed a clinical trial to evaluate a biosafety system based on the principle of Changsha Communique for porcine islet xenotransplantation. Methods: Based on current WHO guidelines and the existing pathogen list for designated pathogen-free (DPF) animals, we designed our updated DPF pathogen screening list. We had selectively inbred a Xiang pig herd for 12 years and confirmed their PERV-C free status and, most recently, their DPF status (Xeno-1). We here in report a clinical trial of ten adult patients (9 M:1 F) with type 1 diabetes who received DPF porcine islet xenotransplantation via the portal vein. Clinically accepted immunosuppressant protocol, tacrolimus, MMF, beletacept and autologous Tregs, were used for the recipients. The recipients were observed for follow-up biosafety evaluations such as infectious signs, microbiological detection, liver function, immunocytes and cytokines as the time schedule post-Tx. The recipients and their spouse were also examined the transmission of porcine endogenous retroviruses (PERV) and the micro-chimerism using PCR and cross-species infection monitoring. Results: PERV-C negative DPF donor piglets were certified in China by CFDA. All recipients and their spouse were minimal 1 year monitoring and up to 5 years. No cross-species pathogen infections and no PERV transmission were observed, and no severe transplant-related side effects were observed. Mild liver function damage was found post transplantation, but recover to normal within 28 days. We did not negatively alter the cytokine and immune responses in patients at 12 months’ post-islet xenotransplantation monitoring. The metabolic outcome improved, and hypoglycemic episodes decreased in all recipients. The exogenous insulin requirement decreased by an average of 45%, and the HbA1c decreased by 22.5% in recipients who received 11,400 ± 1828 IEQ/kg (n=4) at one year post transplantation. Conclusion: This first-in-the-world pilot clinical trial for xenotransplantation biosafety system evaluation of fresh neonatal porcine islets demonstrates that validated DPF PERV-C-free pigs are safe from biohazard risks and transmission and are a valuable donor source of tissue for xenotransplantation. Our data demonstrate that this therapy is safe and efficacious, and these findings provide an important basis for future xenotransplantation studies. This study was supported by the National Grant Program on Key Infectious Disease (2018ZX10301101-003), National Natural Science Foundation of China (Grant No. NSFC 81671752, 31671324, 31970176; Grant No. 2018SK1020). J.C is supported by CAS Pioneer Hundred Talents Program.

Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea

A Pilot Clinical Trial Outcome Of Biosafety System Evaluation For Perv-C Free Porcine Islet Xenotransplantation Based On Principle Of Who "Changsha Communique"

Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes

Pig-To-Primate Islet Xenotransplantation: Past, Present, And Future

A brief review of the current status of pig islet xenotransplantation

Current Status of Genetically Engineered Pig to Monkey Kidney Xenotransplantation in Korea

Current Topics of Relevance to the Xenotransplantation of Free Pig Islets

Pig-Islet Xenotransplantation: Recent Progress and Current Perspectives

What does it take to consent to islet cell xenotransplantation?: Insights from an interview study with type 1 diabetes patients and review of the literature

Establishment of a donor pig for xenotransplantation clinical trials based on the principle of Changsha Communiqué

Pig islet for xenotransplantation in human: structural and physiological compatibility for human clinical application

316.7: Significant Efficacy of GTKO-CD55-CD59-HT Adult Porcine Islets in Treating Diabetic Monkeys with Xenogeneic Islet Transplantation

Combined islet and kidney xenotransplantation for diabetic nephropathy: an update in ongoing research for a clinically relevant application of porcine islet transplantation

Xenotransplantation—the current status and prospects

Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques

Xenotransplantation of porcine islet cells as a potential option for the treatment of type 1 diabetes in the future

Pig Islet Xenotransplantation Into Non-human Primate Model

First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 2a: source pigs--preventing xenozoonoses

Clinical Observation on the Treatment of Type 1 Diabetes with Islet Xenotransplantation

Immunoprotection Strategies in β‐Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation

Immunological Challenges Facing Translation of Alginate Encapsulated Porcine Islet Xenotransplantation to Human Clinical Trials